JP7350061B2 - フューリンインヒビター - Google Patents
フューリンインヒビター Download PDFInfo
- Publication number
- JP7350061B2 JP7350061B2 JP2021513005A JP2021513005A JP7350061B2 JP 7350061 B2 JP7350061 B2 JP 7350061B2 JP 2021513005 A JP2021513005 A JP 2021513005A JP 2021513005 A JP2021513005 A JP 2021513005A JP 7350061 B2 JP7350061 B2 JP 7350061B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- oxy
- pyridin
- dichlorophenyl
- piperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670050P | 2018-05-11 | 2018-05-11 | |
| US62/670,050 | 2018-05-11 | ||
| PCT/EP2019/062098 WO2019215341A1 (en) | 2018-05-11 | 2019-05-10 | Furin inhibitors |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021523941A JP2021523941A (ja) | 2021-09-09 |
| JPWO2019215341A5 JPWO2019215341A5 (https=) | 2022-05-18 |
| JP2021523941A5 JP2021523941A5 (https=) | 2022-05-18 |
| JP7350061B2 true JP7350061B2 (ja) | 2023-10-02 |
Family
ID=66597541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513005A Active JP7350061B2 (ja) | 2018-05-11 | 2019-05-10 | フューリンインヒビター |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11773078B2 (https=) |
| EP (1) | EP3790871B1 (https=) |
| JP (1) | JP7350061B2 (https=) |
| KR (1) | KR102823187B1 (https=) |
| CN (1) | CN112384509B (https=) |
| AU (1) | AU2019267166C1 (https=) |
| BR (1) | BR112020022961A2 (https=) |
| CA (1) | CA3099863A1 (https=) |
| IL (2) | IL278642B2 (https=) |
| MX (1) | MX2020012034A (https=) |
| SG (1) | SG11202010914YA (https=) |
| WO (1) | WO2019215341A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112384509B (zh) | 2018-05-11 | 2024-04-30 | 葛兰素史密斯克莱知识产权发展有限公司 | 弗林蛋白酶抑制剂 |
| WO2021097008A1 (en) * | 2019-11-12 | 2021-05-20 | Bp Asset V, Inc. | Use of pyridyloxypyridines for treating infectious diseases |
| CA3157892A1 (en) * | 2019-11-12 | 2021-05-20 | Keith Wilcoxen | Small molecule furin inhibitors for treating infectious diseases |
| WO2021097002A1 (en) * | 2019-11-12 | 2021-05-20 | Bp Asset V, Inc. | Use of pyridyloxypyrimidines for treating infectious diseases |
| JP2023521032A (ja) * | 2020-04-02 | 2023-05-23 | ビーピー アセット ヴイ，インコーポレーテッド | コロナウイルス感染症を処置するためのフーリンインヒビター |
| FR3110345B1 (fr) | 2020-05-21 | 2024-03-29 | Agence Francaise Pour Le Dev D’Al Ula | Hydrolysat de protéines du tourteau des graines de Moringa peregrina pour son application en tant que médicament, son procédé d’obtention et compositions pharmaceutiques, dermatologiques et cosmétiques. |
| CN117222410A (zh) * | 2021-02-03 | 2023-12-12 | Bp资产V股份有限公司 | 用于吸入的弗林蛋白酶抑制剂的制剂 |
| CN114853640A (zh) * | 2022-05-12 | 2022-08-05 | 马鞍山昂扬新材料科技有限公司 | 2-溴乙基磺酸钠的制备方法 |
| WO2024073576A1 (en) * | 2022-09-29 | 2024-04-04 | Bp Asset V, Inc. | 4-((2-(3,5-dichlorophenyl)-6-((pyrimidin-5-yl)oxy)pyridin-4-yl)methyl)piperazine derivatives as furin inhibitors and uses thereof |
| DE102023126563A1 (de) * | 2023-09-28 | 2025-04-03 | Philipps-Universität Marburg, Körperschaft des öffentlichen Rechts | Hemmstoffe der Proproteinkonvertase Furin, Verfahren zu deren Herstellung und Verwendung |
| CN119119096B (zh) * | 2024-09-09 | 2025-09-16 | 郑州药领医药科技有限公司 | 一种4-((4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)甲基)哌啶-1-甲酸叔丁酯的合成方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005047268A2 (en) | 2003-11-10 | 2005-05-26 | X-Ceptor Therapeutics, Inc. | Substituted pyrimidine compositions and methods of use |
| WO2006031852A1 (en) | 2004-09-13 | 2006-03-23 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| JP2006514118A (ja) | 2002-11-21 | 2006-04-27 | カイロン コーポレイション | ホスホチジルイノシトール（ｐｉ）３−キナーゼインヒビターとしての２，４，６−三置換ピリミジン、および癌の処置におけるその使用 |
| JP2011512380A (ja) | 2008-02-22 | 2011-04-21 | エフ．ホフマン−ラ ロシュ アーゲー | アミロイドβの調節薬 |
| WO2014031438A2 (en) | 2012-08-20 | 2014-02-27 | Merck Sharp & Dohme Corp. | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| JP2018510852A (ja) | 2015-03-06 | 2018-04-19 | ファーマケア，インク． | リシルオキシダーゼ様２阻害剤とその使用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1646160A (zh) | 2002-03-13 | 2005-07-27 | 拜奥根Idec马萨诸塞公司 | 抗αvβ6抗体 |
| CA2586086A1 (en) | 2004-07-23 | 2006-01-23 | Robert E.(Deceased) Smith | Furin inhibitors |
| EP2155894A4 (en) | 2007-05-09 | 2010-08-18 | Burnham Inst Medical Research | HOST PROTEINAS AS A TARGET FOR A THERAPEUTIC STRATEGY AGAINST VIRAL AND BACTERIAL DISEASES |
| CN107011359A (zh) | 2010-10-18 | 2017-08-04 | 塞伦尼斯医疗控股有限公司 | 可用于胆固醇动员的化合物、组合物和方法 |
| WO2013138666A1 (en) | 2012-03-16 | 2013-09-19 | Sanford-Burnham Medical Research Institute | Inhibitors of furin and other pro-protein convertases |
| US9266828B2 (en) | 2012-03-16 | 2016-02-23 | Sanford-Burnham Medical Research Institute | Inhibitors of Furin and other pro-protein convertases |
| WO2014152716A1 (en) | 2013-03-15 | 2014-09-25 | President And Fellows Of Harvard College | Substituted heterocyclic compounds for treating or preventing viral infections |
| CN107441094B (zh) | 2017-08-08 | 2020-05-22 | 南方医科大学 | 尼罗替尼作为治疗登革病毒感染的药物及其制药用途 |
| CN112384509B (zh) | 2018-05-11 | 2024-04-30 | 葛兰素史密斯克莱知识产权发展有限公司 | 弗林蛋白酶抑制剂 |
| CA3157892A1 (en) | 2019-11-12 | 2021-05-20 | Keith Wilcoxen | Small molecule furin inhibitors for treating infectious diseases |
-
2019
- 2019-05-10 CN CN201980046497.1A patent/CN112384509B/zh active Active
- 2019-05-10 BR BR112020022961-0A patent/BR112020022961A2/pt unknown
- 2019-05-10 US US17/054,491 patent/US11773078B2/en active Active
- 2019-05-10 JP JP2021513005A patent/JP7350061B2/ja active Active
- 2019-05-10 AU AU2019267166A patent/AU2019267166C1/en active Active
- 2019-05-10 MX MX2020012034A patent/MX2020012034A/es unknown
- 2019-05-10 IL IL278642A patent/IL278642B2/en unknown
- 2019-05-10 WO PCT/EP2019/062098 patent/WO2019215341A1/en not_active Ceased
- 2019-05-10 IL IL302997A patent/IL302997B2/en unknown
- 2019-05-10 KR KR1020207035245A patent/KR102823187B1/ko active Active
- 2019-05-10 SG SG11202010914YA patent/SG11202010914YA/en unknown
- 2019-05-10 EP EP19725058.2A patent/EP3790871B1/en active Active
- 2019-05-10 CA CA3099863A patent/CA3099863A1/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006514118A (ja) | 2002-11-21 | 2006-04-27 | カイロン コーポレイション | ホスホチジルイノシトール（ｐｉ）３−キナーゼインヒビターとしての２，４，６−三置換ピリミジン、および癌の処置におけるその使用 |
| WO2005047268A2 (en) | 2003-11-10 | 2005-05-26 | X-Ceptor Therapeutics, Inc. | Substituted pyrimidine compositions and methods of use |
| WO2006031852A1 (en) | 2004-09-13 | 2006-03-23 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| JP2011512380A (ja) | 2008-02-22 | 2011-04-21 | エフ．ホフマン−ラ ロシュ アーゲー | アミロイドβの調節薬 |
| WO2014031438A2 (en) | 2012-08-20 | 2014-02-27 | Merck Sharp & Dohme Corp. | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| JP2018510852A (ja) | 2015-03-06 | 2018-04-19 | ファーマケア，インク． | リシルオキシダーゼ様２阻害剤とその使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019267166A1 (en) | 2020-11-26 |
| IL302997B1 (en) | 2024-04-01 |
| IL278642B2 (en) | 2023-10-01 |
| IL302997A (en) | 2023-07-01 |
| IL278642A (https=) | 2020-12-31 |
| IL278642B1 (en) | 2023-06-01 |
| BR112020022961A2 (pt) | 2021-02-17 |
| KR102823187B1 (ko) | 2025-06-20 |
| KR20210021298A (ko) | 2021-02-25 |
| CA3099863A1 (en) | 2019-11-14 |
| EP3790871A1 (en) | 2021-03-17 |
| EP3790871C0 (en) | 2024-01-24 |
| CN112384509A (zh) | 2021-02-19 |
| US11773078B2 (en) | 2023-10-03 |
| CN112384509B (zh) | 2024-04-30 |
| EP3790871B1 (en) | 2024-01-24 |
| MX2020012034A (es) | 2021-04-12 |
| SG11202010914YA (en) | 2020-12-30 |
| JP2021523941A (ja) | 2021-09-09 |
| AU2019267166B2 (en) | 2023-06-15 |
| AU2019267166C1 (en) | 2023-11-30 |
| WO2019215341A1 (en) | 2019-11-14 |
| US20220315556A1 (en) | 2022-10-06 |
| IL302997B2 (en) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7350061B2 (ja) | フューリンインヒビター | |
| CN104379574B (zh) | 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物 | |
| CN104302634B (zh) | 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物 | |
| JP7051829B2 (ja) | Ｄｎｍｔ１の阻害剤としての置換ピリジン | |
| CN110049983B (zh) | 药物化合物 | |
| CN110167935B (zh) | 作为αV整合素抑制剂的3-经取代的丙酸 | |
| CN113227068A (zh) | Glp-1r激动剂及其用途 | |
| JP6795588B2 (ja) | ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド | |
| TW201414737A (zh) | 作爲激酶抑制劑之咪唑并三□甲腈 | |
| WO2019001572A1 (zh) | Rho 相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 | |
| TW201443023A (zh) | 作爲ｒｏｃｋ抑制劑之酞□酮及異喹啉酮 | |
| CN102548557A (zh) | 用于降低β-淀粉状蛋白生成的化合物 | |
| CN116096719B (zh) | 作为alk5抑制剂的哒嗪基氨基衍生物 | |
| CN110003178A (zh) | 二杂芳基化合物及其用途 | |
| JP6885968B2 (ja) | ブロモドメイン阻害薬としてのピリジンジカルボキサミド誘導体 | |
| JP6954921B2 (ja) | ブロモドメイン阻害薬としてのピリジル誘導体 | |
| CN116390917A (zh) | Mrgx2拮抗剂 | |
| CN114728941A (zh) | 作为alk5抑制剂的经取代的1,5-萘啶或喹啉 | |
| CN113195467A (zh) | 适用作alk5抑制剂的萘啶和喹啉衍生物 | |
| CN107922407A (zh) | 呼吸道合胞病毒抑制剂 | |
| KR20240133727A (ko) | Nrf2 활성화 작용을 갖는 함질소 헤테로환 화합물 | |
| KR20260023023A (ko) | Wrn 억제제 | |
| RU2799824C2 (ru) | Ингибиторы фурина | |
| HK40047035A (en) | Furin inhibitors | |
| HK40047035B (en) | Furin inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220510 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220510 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230421 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230420 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230721 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230901 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230912 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7350061 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R154 | Certificate of patent or utility model (reissue) |
Free format text: JAPANESE INTERMEDIATE CODE: R154 |